Caxton Associates (New York)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$590K	Buy	+1,797	New	+$610K	0.02%	301
2024 Q3	–	Sell	-3,785	Closed	-$1.03M	–	529
2024 Q2	$1.03M	Buy	+3,785	New	+$1.1M	0.04%	243
2024 Q1	–	Sell	-10,677	Closed	-$3.45M	–	468
2023 Q4	$3.45M	Buy	10,677 +8,813	+473%	+$2.76M	0.18%	72
2023 Q3	$668K	Buy	+1,864	New	+$719K	0.09%	208
2023 Q1	–	Sell	-2,822	Closed	-$1.19M	–	502
2022 Q4	$1.19M	Buy	2,822 +2,003	+245%	+$808K	0.09%	91
2022 Q3	$342K	Sell	819 -488	-37%	-$243K	0.06%	303
2022 Q2	$647K	Buy	1,307 +754	+136%	+$393K	0.08%	211
2022 Q1	$311K	Sell	553 -129	-19%	-$77.8K	0.03%	355
2021 Q4	$515K	Buy	+682	New	+$510K	0.07%	265
2021 Q3	–	Sell	-1,234	Closed	-$795K	–	455
2021 Q2	$795K	Buy	1,234 +253	+26%	+$154K	0.1%	101
2021 Q1	$560K	Buy	+981	New	+$581K	0.05%	143
2017 Q3	–	Sell	-2,903	Closed	-$657K	–	498
2017 Q2	$657K	Buy	+2,903	New	+$633K	0.05%	236